Across TCGA pan-cancer cohorts, MIR487A Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MIR487A data layer compared with 9 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher MIR487A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MIR487A expression acts as an unfavorable survival marker.
SKCM are the cancer types where MIR487A Mutation most reproducibly stratifies survival.